Get the Stockscreener App
7.07
3.68%
-0.27
Pre-market:
7.13
0.06
+0.85%
Novavax Inc stock is traded at $7.07, with a volume of 6.97M.
It is down -3.68% in the last 24 hours and up +10.30% over the past month.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.
See More
Previous Close:
$7.34
Open:
$7.33
24h Volume:
6.97M
Relative Volume:
0.85
Market Cap:
$1.15B
Revenue:
$847.25M
Net Income/Loss:
$-284.86M
P/E Ratio:
-3.0873
EPS:
-2.29
Net Cash Flow:
$-112.35M
1W Performance:
-2.48%
1M Performance:
+10.30%
6M Performance:
-19.38%
1Y Performance:
-52.96%
1-Day Range:
$6.92
$7.34
1-Week Range:
$6.84
$7.62
52-Week Range:
$5.01
$23.86
Novavax Inc Stock (NVAX) Company Profile
Name
Novavax Inc
Sector
Industry
Phone
240-268-2000
Address
700 QUINCE ORCHARD ROAD, GAITHERSBURG, MD
Compare NVAX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVAX
Novavax Inc
|
7.07 | 1.20B | 847.25M | -284.86M | -112.35M | -2.29 |
|
ONC
Beone Medicines Ltd Adr
|
245.93 | 25.76B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.43 | 114.53B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.415 | 40.54M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
84.10 | 6.44B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.81 | 65.13B | 14.09B | 4.50B | 2.96B | 39.28 |
Novavax Inc Stock (NVAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-28-25 | Initiated | BTIG Research | Buy |
| Jul-30-24 | Downgrade | JP Morgan | Neutral → Underweight |
| May-10-24 | Upgrade | BofA Securities | Underperform → Neutral |
| May-10-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Aug-09-23 | Upgrade | B. Riley Securities | Neutral → Buy |
| Apr-20-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Mar-01-23 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jan-09-23 | Reiterated | B. Riley Securities | Buy |
| Dec-30-22 | Reiterated | H.C. Wainwright | Buy |
| Dec-02-22 | Initiated | Jefferies | Hold |
| Sep-22-22 | Downgrade | JP Morgan | Neutral → Underweight |
| May-20-22 | Initiated | BofA Securities | Underperform |
| Feb-23-22 | Reiterated | B. Riley Securities | Buy |
| Feb-22-22 | Resumed | Jefferies | Buy |
| Jan-21-22 | Initiated | Cowen | Outperform |
| May-12-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-14-20 | Initiated | Jefferies | Buy |
| Aug-06-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-05-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-05-20 | Downgrade | Ladenburg Thalmann | Neutral → Sell |
| Jul-16-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-20 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Jun-29-20 | Reiterated | B. Riley FBR | Buy |
| Jun-29-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-05-20 | Upgrade | JP Morgan | Underweight → Neutral |
| May-28-20 | Reiterated | B. Riley FBR | Buy |
| May-12-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-30-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-27-19 | Resumed | B. Riley FBR | Buy |
| Aug-14-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-28-19 | Downgrade | Piper Jaffray | Overweight → Underweight |
| Dec-18-18 | Initiated | Ladenburg Thalmann | Buy |
| Dec-11-18 | Initiated | Oppenheimer | Outperform |
| Nov-26-18 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Sep-21-18 | Upgrade | JP Morgan | Underweight → Overweight |
| Mar-29-18 | Upgrade | Seaport Global Securities | Neutral → Buy |
View All
Novavax Inc Stock (NVAX) Latest News
Moderna's New COVID Vaccine Secures FDA-Clearance For Seniors, At-Risk Individuals - Benzinga
Novavax (NVAX) Sees Surge in Bullish Option Activity | NVAX Stoc - GuruFocus
US CDC continues to recommend COVID vaccines for children, contradicts Kennedy - marketscreener.com
Novavax (NVAX) Sees Surge in Bullish Option Activity | NVAX Stock News - GuruFocus
RFK Jr. Drops COVID Vaccine Recommendation For Healthy Kids, But Experts Warn Of Major Risks - Benzinga
Novavax to Participate in Upcoming Investor Conferences - Quantisnow
Novavax to Participate in Upcoming Investor Conferences | NVAX S - GuruFocus
Novavax Announces June Presentations at Jefferies and Goldman Sachs Conferences | NVAX Stock News - Stock Titan
Novavax Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Novavax eliminates COO role, parts ways with longtime exec amid business model shift - The Business Journals
(NVAX) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Novavax Eliminates COO Position, Trizzino to Consult - TipRanks
Novavax IncEliminates COO Position, Terminates John TrizzinoSEC Filing - marketscreener.com
Here's Why Novavax (NVAX) is a Strong Momentum Stock - Yahoo Finance
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Novavax COVID-19 vaccine approved by the FDA - MSN
Gaithersburg-Based Novavax Receives FDA Approval for COVID-19 Vaccine for High-Risk Groups - The MoCo Show -
JPMorgan Maintains Underweight Rating on Novavax (NVAX) Stock Despite Positive News - MSN
Novavax Target of Unusually High Options Trading (NASDAQ:NVAX) - Defense World
BofA Reiterates Hold Rating on Novavax (NVAX) Stock - MSN
Analysts Think These Stocks Could More Than Double in Value - MarketBeat
Rx Rundown: BioMarin, Novavax, CellCentric and more - Medical Marketing and Media
Novavax, Inc. (NASDAQ:NVAX) Given Average Rating of “Hold” by Analysts - Defense World
NVAX Stock Surges on Securing FDA Approval for COVID-19 Vaccine - MSN
NVAX July 3rd Options Begin Trading - Nasdaq
New Vaccine Framework Avoided Worst-Case Scenario, Analysts Say - insights.citeline.com
Novavax: Nuvaxovid FDA Approval Unlocks Several Bullish Stimuli (NASDAQ:NVAX) - Seeking Alpha
Novavax Soars After Covid Vaccine Secures Full FDA Approval - MSN
Novavax Stock (NVAX) Shoots 15% Higher as Covid Vaccine Jab Gets FDA Green Light - The Globe and Mail
US FDA advisers to consider if new COVID shots should target LP.8.1 subvariant - marketscreener.com
Novavax, Inc. (NASDAQ:NVAX) Shares Fly 29% But Investors Aren't Buying For Growth - simplywall.st
Novavax’s COVID-19 Vaccine Label Narrowed After Political Officials Intervened - insights.citeline.com
Dow Surges Over 100 Points Despite Moody's US Downgrade: Fear Index Remains In 'Greed' Zone - Benzinga
US Markets Show Mixed Signals Amid Rating Downgrades And Rising Earnings - Finimize
Novavax Receives FDA Approval for Nuvaxovid Vaccine for High-Risk Populations - madisongraph.com
Novavax gets FDA nod for Nuvaxovid vaccine in high-risk groups By Investing.com - Investing.com South Africa
JPMorgan maintains Novavax stock Underweight with $7 target By Investing.com - Investing.com Nigeria
FDA Clears Novavax, Inc. (NVAX)’s COVID-19 Vaccine with Usage Restrictions - MSN
Third COVID Vaccine Gets Approved for Adults 65 and Over - AARP
These Stocks Moved the Most Today: Nvidia, Tesla, UnitedHealth, JPMorgan, SMCI, Palantir, Novavax, and More - Barron's
With FDA vaccine nod, Novavax takes ACIP of new COVID-19 rules - BioWorld MedTech
FDA Approval Boosts Novavax (NVAX) with $200M Milestone | NVAX S - GuruFocus
Novavax, Shake Shack, solar stocks: Trending Tickers - Yahoo Finance
Novavax gets FDA nod for Nuvaxovid vaccine in high-risk groups - Investing.com Australia
Novavax Shares Jump 17% FDA Grants Full Approval to COVID Vaccine - Yahoo Finance
Stocks Mixed, Treasury Bonds Slip On Moody's US Downgrade: What's Driving Markets Monday? - Benzinga
US Approves Novavax Covid Jab After Delay, Adds Restrictions - Barron's
Novavax secures FDA approval for COVID-19 vaccine - Investing.com Australia
Novavax secures FDA approval for COVID-19 vaccine By Investing.com - Investing.com Nigeria
FDA approves Novavax COVID vaccine with new conditions - Reuters
Novavax’s COVID vaccine gets FDA approval, but with limits - BioPharma Dive
Novavax Inc Stock (NVAX) Financials Data
Revenue
Net Income
Cash Flow
EPS
6.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):